Vitrolife AB (publ)

BATS-CHIXE:VITRS Stock Report

Market Cap: SEK 18.6b

Vitrolife Valuation

Is VITRS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VITRS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SEK 206.55
Fair Value
34.8% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: VITRS (SEK134.7) is trading below our estimate of fair value (SEK206.55)

Significantly Below Fair Value: VITRS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VITRS?

Key metric: As VITRS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for VITRS. This is calculated by dividing VITRS's market cap by their current earnings.
What is VITRS's PE Ratio?
PE Ratio40.8x
EarningsSEK 455.00m
Market CapSEK 18.57b

Price to Earnings Ratio vs Peers

How does VITRS's PE Ratio compare to its peers?

The above table shows the PE ratio for VITRS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.5x
GNS Genus
86.8x24.78%UK£1.7b
BVXP Bioventix
16.2xn/aUK£127.5m
PRTC PureTech Health
9.1x-64.97%UK£341.3m
HCM HUTCHMED (China)
6x-64.36%UK£2.1b
VITRS Vitrolife
40.8x21.74%SEK 18.6b

Price-To-Earnings vs Peers: VITRS is expensive based on its Price-To-Earnings Ratio (40.8x) compared to the peer average (29.5x).

Price to Earnings Ratio vs Industry

How does VITRS's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies5PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: VITRS is expensive based on its Price-To-Earnings Ratio (40.8x) compared to the European Biotechs industry average (20.2x).

Price to Earnings Ratio vs Fair Ratio

What is VITRS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VITRS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio40.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VITRS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VITRS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 134.70
SEK 199.25
+47.92%
18.07%SEK 240.00SEK 160.00n/a4
Sep ’26SEK 138.10
SEK 202.50
+46.63%
18.60%SEK 240.00SEK 160.00n/a4
Aug ’26n/a
SEK 202.50
0%
18.60%SEK 240.00SEK 160.00n/a4
Jul ’26SEK 135.90
SEK 228.75
+68.32%
14.61%SEK 265.00SEK 175.00n/a4
Jun ’26n/a
SEK 242.40
0%
6.82%SEK 265.00SEK 227.00n/a5
May ’26n/a
SEK 243.40
0%
7.26%SEK 265.00SEK 227.00n/a5
Apr ’26n/a
SEK 256.60
0%
5.46%SEK 268.00SEK 230.00n/a5
Mar ’26n/a
SEK 269.20
0%
2.43%SEK 278.00SEK 260.00n/a5
Feb ’26n/a
SEK 270.20
0%
2.83%SEK 280.00SEK 260.00n/a5
Jan ’26n/a
SEK 273.33
0%
3.45%SEK 280.00SEK 260.00n/a3
Dec ’25n/a
SEK 273.33
0%
3.45%SEK 280.00SEK 260.00n/a3
Nov ’25n/a
SEK 271.67
0%
3.13%SEK 280.00SEK 260.00n/a3
Oct ’25n/a
SEK 271.67
0%
3.13%SEK 280.00SEK 260.00SEK 134.703
Sep ’25n/a
SEK 261.67
0%
3.93%SEK 275.00SEK 250.00SEK 138.103
Aug ’25n/a
SEK 261.67
0%
3.93%SEK 275.00SEK 250.00n/a3
Jul ’25SEK 174.60
SEK 231.67
+32.68%
10.33%SEK 265.00SEK 210.00SEK 135.903
Jun ’25n/a
SEK 231.67
0%
10.33%SEK 265.00SEK 210.00n/a3
May ’25n/a
SEK 231.67
0%
10.33%SEK 265.00SEK 210.00n/a3
Apr ’25n/a
SEK 248.33
0%
6.64%SEK 270.00SEK 230.00n/a3
Mar ’25n/a
SEK 248.33
0%
6.64%SEK 270.00SEK 230.00n/a3
Feb ’25SEK 172.05
SEK 241.67
+40.46%
8.67%SEK 270.00SEK 220.00n/a3
Jan ’25n/a
SEK 255.00
0%
7.34%SEK 280.00SEK 235.00n/a3
Dec ’24n/a
SEK 250.00
0%
9.80%SEK 280.00SEK 220.00n/a3
Nov ’24n/a
SEK 256.67
0%
12.86%SEK 300.00SEK 220.00n/a3
Oct ’24n/a
SEK 281.67
0%
5.09%SEK 300.00SEK 265.00n/a3
SEK 195.76
Fair Value
31.2% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 07:18
End of Day Share Price 2025/10/01 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vitrolife AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
null nullABG Sundal Collier Sponsored
Kallum TitchmarshBofA Global Research